ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 4, 2018 to discuss its first quarter operating results. Management also will provide a brief update on the business.

Conference Call InformationTo access the live call by phone, dial 719-325-4799; the conference ID is 2070974. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com. Following the webcast, a replay of the call will be available at the same location through May 18, 2018.

About ImmunoGen, Inc.ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla®, and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180420005134/en/

For InvestorsImmunoGen, Inc.Sarah Kiely, [e-mail] MediaImmunoGen, Inc.Courtney O'Konek, [e-mail] Consulting, Inc.Robert Stanislaro, [e-mail]